高温度稳定性磁电复合材料的制备及其性能

以锆钛酸铅(PZT)为压电相,分别以Ni和非晶铁合金(Metal-glass)为磁致伸缩相,采用焊接的方法制备了层状磁电复合材料Ni/PZT/Ni和Metal-glass/PZT/Metal-glass,并研究其在0~100℃范围内的磁电效应.结果表明,通过焊接复合得到的2种层状磁电复合材料都表现出良好的温度稳定性,在0~100℃范围内磁电电压系数基本保持恒定,有望用于高温磁电器件的设计.福建省自然科学基金(2016J01256

Development of Database for Pesticide Surfactant

本论文建立了农药用表面活性剂数据库并研究其在农药制剂中的应用，合成并测定了马来松香系列表面活性剂的亲水亲油平衡值HLB值，采用分子模拟技术筛选了家蝇GABAA受体萜类抑制剂先导化合物。具体研究内容及进展如下： 1. 研究表面活性剂在农药制剂中的应用规律，提出了一种用溶剂的溶解度参数δ进行乳化溶剂所需的HLB值的预测的方法。通过HLB值预测公式的比较研究，选择了一种预测准确度较高的有效链长基团加和法预测表面活性剂的HLB值。以数据的原始性和公开性为数据收集的基本原则，对农药用表面活性剂数据进行了系统性的收集。通过对现有数据库管理系统的分析，选用Access关系数据库管理系统建立和管理农药用表面活性剂数据库，并利用Visual Basic 开发了数据库前端应用程序，建立了HLB值和cmc值预测模块。最后通过实例验证了数据库管理系统的准确性和实用性。 2. 合成并测定了马来松香系列表面活性剂的HLB值。以马来松香酸和聚氧乙烯醚为原料，合成了一系列马来松香酸聚氧乙烯酯非离子表面活性剂，测定了其HLB值和cmc值，并比较了HLB值的实验值和预测值。分别用三乙醇胺、二乙醇胺、三乙胺和氢氧化钠皂化马来松香酸聚氧乙烯酯，得到四类新型阴离子表面活性剂，并测定了其表面性能。 3. 采用分子模拟技术进行了家蝇GABAA受体萜类抑制剂先导化合物的筛选研究。用距离比较法（DISCOtech）构建的家蝇GABAA受体萜类抑制剂药效团模型为基础建立了提问结构，以三维数据库搜索软件3DFS为工具，在三维结构中草药数据库(TCMD)中进行了搜索。对搜索结果使用改进的Linpinsky 五原则进行筛选，挑选出21个化合物，进行CoMFA活性预测。结果分析表明，预测得到的化合物的生物活性与文献实际报道的生物活性数据趋势相一致，对3DFS三维数据库搜索出的化合物进行类杀虫剂筛选，并用CoMFA进行生物活性预测的方法是一种有效的筛选先导化合物的方法

家蝇GABAA受体萜类抑制剂先导化合物的筛选

用距离比较法（DISCOtech）构建的家蝇GABAA受体萜类抑制剂药效团模型为基础建立了提问结构,以三维数据库搜索软件3DFS为工具,在三维结构中草药数据库（TCMD）中进行了搜索。对搜索结果使用改进的Linpinsky五原则进行筛选,挑选21个化合物进行CoMFA活性预测,活性预测值较高。结果分析表明,3DFS-类杀虫剂筛选-CoMFA活性预测生物活性方法是一种有效的筛选先导化合物的方法

家蝇GABA_A受体萜类抑制剂先导化合物的筛选

用距离比较法(DISCOtech)构建的家蝇GABA_A受体萜类抑制剂药效团模型为基础建立了提问结构,以三维数据库搜索软件3DFS为工具,在三维结构中草药数据库(TCMD)中进行了搜索。对搜索结果使用改进的Linpinsky五原则进行筛选,挑选21个化合物进行CoMFA活性预测,活性预测值较高。结果分析表明,3DFS-类杀虫剂筛选-CoMFA活性预测生物活性方法是一种有效的筛选先导化合物的方法

家蝇GABA_A受体萜类抑制剂先导化合物的筛选

用距离比较法（DISCOtech）构建的家蝇GABAA受体萜类抑制剂药效团模型为基础建立了提问结构,以三维数据库搜索软件3DFS为工具,在三维结构中草药数据库（TCMD）中进行了搜索。对搜索结果使用改进的Linpinsky五原则进行筛选,挑选21个化合物进行CoMFA活性预测,活性预测值较高。结果分析表明,3DFS-类杀虫剂筛选-CoMFA活性预测生物活性方法是一种有效的筛选先导化合物的方法

家蝇GABAA受体萜类抑制剂先导化合物的筛选

用距离比较法（DISCOtech）构建的家蝇GABAA受体萜类抑制剂药效团模型为基础建立了提问结构,以三维数据库搜索软件3DFS为工具,在三维结构中草药数据库（TCMD）中进行了搜索。对搜索结果使用改进的Linpinsky五原则进行筛选,挑选21个化合物进行CoMFA活性预测,活性预测值较高。结果分析表明,3DFS-类杀虫剂筛选-CoMFA活性预测生物活性方法是一种有效的筛选先导化合物的方法

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials